WuXi Biologics partners with HanchorBio on next-gen immunotherapies

WuXi Biologics is collaborating with biotechnology company HanchorBio to progress the development and manufacture of multiple next-generation bi- and multi-functional fusion proteins.

The partnership focuses on scaling HanchorBio’s fusion protein portfolio, derived from its Fc-Based Designer Biologics (FBDB) platform, to advance its oncology and autoimmune pipelines.

Under the agreement, WuXi Biologics will provide end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing.

Dr Chris Chen, Chief Executive Officer of WuXi Biologics, said: “By leveraging our industry-leading technology platforms, proven expertise, and unwavering commitment to quality, we strive to accelerate the development of HanchorBio’s innovative bi-/multi fusion proteins and help bring transformative therapies to patients worldwide.”

HanchorBio anticipates the collaboration with WuXi Biologics will reduce development timelines and support flexibility across its clinical programmes. These include multi-functional biologics designed to activate both innate and adaptive immune pathways to overcome the current challenges of anti-PD1/L1 immunotherapies.

Scott Liu, Founder, Chairman and Chief Executive Officer of HanchorBio, said: “This partnership with WuXi Biologics strengthens our ability to translate platform-driven innovation into high-quality clinical and commercial assets.

“As we advance multiple next-generation fusion protein programmes, execution speed, manufacturing reliability and scalability are critical. WuXi Biologics’ proven expertise in complex biologics and global development makes them a strong strategic partner as we build a differentiated, multi-asset immunotherapy pipeline.”

Last August, the European Medicines Agency (EMA) authorised WuXi Biologics’ commercial biologic manufacturing in Ireland, after it gained full GMP authorisation in 2024. The site is an important manufacturing hub in WuXi Biologics’ global network and houses advanced 6,000L perfusion and 48,000L fed-batch capacity.